EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

11C-Methionine uptake in meningiomas after stereotactic radiotherapy

Hanne-Rinck Jeltema, Bart R J van Dijken, Katalin Tamási, Gea Drost, Mart A A M Heesters, Anouk van der Hoorn, Andor W J M Glaudemans, J Marc C van Dijk

Annals of Nuclear Medicine · 2024

DOI: 10.1007/s12149-024-01932-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Nuclear Medicine, 2024. Verfasst von Hanne-Rinck Jeltema und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700RB, Groningen, The Nethe…. Hauptthemen laut MEDLINE: Meningioma, Methionine, Radiosurgery, Positron-Emission Tomography. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

11 C-Methionine positron emission tomography (MET-PET) is used for stereotactic radiotherapy planning in meningioma patients. The role of MET-PET during subsequent follow-up (FU) is unclear. We analyzed the uptake of 11 C-Methionine before and after stereotactic radiotherapy (SRT) in patients with a complex meningioma and investigated if there was a difference between patients with progressive disease (PD) and stable disease (SD) during FU.

Methods

This retrospective study investigates 62 MET-PETs in 29 complex meningioma patients. Standardized uptake value (SUV) max and SUV peak tumor-to-normal ratios (T/N-ratios) were calculated, comparing the tumor region with both the mirroring intracranial area and the right frontal gray matter. The difference in 11 C-Methionine uptake pre- and post-SRT was analyzed, as well as the change in uptake between PD or SD.

Results

Median (IQR) FU duration was 67 months (50.5–91.0). The uptake of 11 C-Methionine in meningiomas remained increased after SRT. Neither a statistically significant difference between MET-PETs before and after SRT was encountered, nor a significant difference in one of the four T/N-ratios between patients with SD versus PD with median (IQR) SUV max T/N R front 2.65 (2.13–3.68) vs 2.97 (1.55–3.54) [ p = 0.66]; SUV max T/N mirror 2.92 (2.19–3.71) vs 2.95 (1.74–3.60) [ p = 0.61]; SUV peak T/N R front 2.35 (1.64–3.40) vs 2.25 (1.44–3.74) [ p = 0.80]; SUV peak T/N mirror 2.38 (1.91–3.36) vs 2.35 (1.56–3.72) [ p = 0.95].

Conclusions

Our data do not support use of MET-PET during FU of complex intracranial meningiomas after SRT. MET-PET could not differentiate between progressive or stable disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaMethionineRadiosurgeryPositron-Emission TomographyHumansMaleFemaleRetrospective StudiesMiddle AgedAgedBiological TransportMeningeal NeoplasmsAdultDisease Progression

Stichwörter der Autor:innen

11C-MethionineFollow-upMET-PETMeningiomaStereotactic radiotherapy

Substanzen

Methioninecarbon-11 methionine

Autor:innen und Institutionen

  • Department of Neurosurgery, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700RB, Groningen, The Netherlands. j.r.jeltema@umcg.nl.
  • Department of Radiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Neurosurgery, University of Groningen, University Medical Center Groningen, Hanzeplein 1, P.O. Box 30.001, 9700RB, Groningen, The Netherlands.
  • Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Radiotherapy, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Zitieren

APA

Jeltema, H. R., van Dijken, B. R. J., Tamási, K., Drost, G., Heesters, M. A. A. M., van der Hoorn, A., Glaudemans, A. W. J. M., & van Dijk, J. M. C. (2024). 11C-Methionine uptake in meningiomas after stereotactic radiotherapy. Annals of Nuclear Medicine. https://doi.org/10.1007/s12149-024-01932-6

Vancouver

Jeltema HR, van Dijken BRJ, Tamási K, Drost G, Heesters MAAM, van der Hoorn A, et al. 11C-Methionine uptake in meningiomas after stereotactic radiotherapy. Annals of Nuclear Medicine. 2024. doi:10.1007/s12149-024-01932-6

BibTeX
@article{Jeltema2024,
  author = {Jeltema, Hanne-Rinck and van Dijken, Bart R J and Tamási, Katalin and Drost, Gea and Heesters, Mart A A M and van der Hoorn, Anouk and Glaudemans, Andor W J M and van Dijk, J Marc C},
  title = {11C-Methionine uptake in meningiomas after stereotactic radiotherapy},
  journal = {Annals of Nuclear Medicine},
  year = {2024},
  doi = {10.1007/s12149-024-01932-6}
}
Kostenlos starten →